Michael A Morse


Ontology type: schema:Person     


Person Info

NAME

Michael A

SURNAME

Morse

Publications in SciGraph latest 50 shown

  • 2018-12 Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers in BREAST CANCER RESEARCH
  • 2018-10-29 Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS) in CLINICAL AND TRANSLATIONAL ONCOLOGY
  • 2018-02 CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018 Immune Checkpoint Combinations with Inflammatory Pathway Modulators in EARLY PHASE CANCER IMMUNOTHERAPY
  • 2017-12 Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2017-03 Phase I study of pazopanib plus TH-302 in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-12 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-12 Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-12 A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-11 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-09 A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-08 Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2016-02 The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer in CURRENT COLORECTAL CANCER REPORTS
  • 2016-01-28 X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity in CELL DEATH & DISEASE
  • 2015-12 Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-12 Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth in BREAST CANCER RESEARCH
  • 2015-12 Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-08 Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-06 CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-12 Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12 A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12 Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-08 Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma in ANNALS OF SURGICAL ONCOLOGY
  • 2014-08 Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2014-05 Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States in ANNALS OF SURGICAL ONCOLOGY
  • 2014-04 Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer in INVESTIGATIONAL NEW DRUGS
  • 2013-12 Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer in CURRENT COLORECTAL CANCER REPORTS
  • 2013-12 Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-11 High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-11 Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-10 Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2013-08 Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-06 Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-01 Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-12 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines in BMC CANCER
  • 2012-12 First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-11 Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-08 Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-07 A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-06 Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells in BREAST CANCER RESEARCH
  • 2012-01 Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function in CANCER GENE THERAPY
  • 2011-04 Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines in IMMUNOLOGIC RESEARCH
  • 2011-02 Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-02 A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-01-07 Depletion of Human Regulatory T Cells in REGULATORY T CELLS
  • 2010-01 Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody in BRITISH JOURNAL OF CANCER
  • 2009-12 Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.189509.c", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.265008.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414179.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26009.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4367.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416555.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.17088.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.267153.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413696.f", 
            "type": "Organization"
          }
        ], 
        "familyName": "Morse", 
        "givenName": "Michael A", 
        "id": "sg:person.013700705377.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T13:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_1361.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.013700705377.06'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.013700705377.06'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.013700705377.06'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.013700705377.06'


     

    This table displays all metadata directly associated to this object as RDF triples.

    34 TRIPLES      10 PREDICATES      20 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.013700705377.06 schema:affiliation N660e1006d5804e2ea35030151ccc9198
    2 https://www.grid.ac/institutes/grid.10417.33
    3 https://www.grid.ac/institutes/grid.17088.36
    4 https://www.grid.ac/institutes/grid.26009.3d
    5 https://www.grid.ac/institutes/grid.265008.9
    6 https://www.grid.ac/institutes/grid.267153.4
    7 https://www.grid.ac/institutes/grid.413696.f
    8 https://www.grid.ac/institutes/grid.414179.e
    9 https://www.grid.ac/institutes/grid.416555.6
    10 https://www.grid.ac/institutes/grid.4367.6
    11 schema:familyName Morse
    12 schema:givenName Michael A
    13 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06
    14 schema:sdDatePublished 2019-03-07T13:34
    15 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    16 schema:sdPublisher N2e7c6b624a404d879f868e7e69ed3886
    17 sgo:license sg:explorer/license/
    18 sgo:sdDataset persons
    19 rdf:type schema:Person
    20 N2e7c6b624a404d879f868e7e69ed3886 schema:name Springer Nature - SN SciGraph project
    21 rdf:type schema:Organization
    22 N660e1006d5804e2ea35030151ccc9198 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
    23 sgo:isCurrent true
    24 rdf:type schema:OrganizationRole
    25 https://www.grid.ac/institutes/grid.10417.33 schema:Organization
    26 https://www.grid.ac/institutes/grid.17088.36 schema:Organization
    27 https://www.grid.ac/institutes/grid.189509.c schema:Organization
    28 https://www.grid.ac/institutes/grid.26009.3d schema:Organization
    29 https://www.grid.ac/institutes/grid.265008.9 schema:Organization
    30 https://www.grid.ac/institutes/grid.267153.4 schema:Organization
    31 https://www.grid.ac/institutes/grid.413696.f schema:Organization
    32 https://www.grid.ac/institutes/grid.414179.e schema:Organization
    33 https://www.grid.ac/institutes/grid.416555.6 schema:Organization
    34 https://www.grid.ac/institutes/grid.4367.6 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...